The IMU Research&Development (R&D) Tax Incentive refund relating to year ending 30.06.23 for $11,741,527 is due to be banked any day now, the next quarterly report for Item 8.4 should include the additional 11,741 as available funding in the total.
Management announced the manufacturing divestment transaction to yield Imugene approximately A$49.0 million (USD$32 million) in cost savings from salaries, drug manufacturing, and overhead costs.(I assume this is for one year) or A$12.25 million per quarter.
Therefore future quarterly reports for Item 8.1 should indicate a reduction of 12,250 per quarter.
Item 8.5 for the June 2024 quarterly report should indicate IMU has 9 estimated quarters of funding available (until June 2026), i.e. $112,863 divided by $12,962.
It would be nice if management would allow shareholders to see a cash flow report for the next 2 years.
Regards.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-104
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
0.002(3.13%) |
Mkt cap ! $368.1M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 5.0¢ | 4.8¢ | $373.3K | 7.641M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 2111375 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 5196196 | 36 |
View Market Depth
| Last trade - 14.27pm 07/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |